Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer. For locally advanced and advanced NSCLC, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-targeted therapy has been the first choice for NSCLC patients with EGFR mutations. TKIs, as targeted dr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuhong Ma, Feng Zhang, Jin Li, Juan Li, Yanhua Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	EGFR-TKI resistance phosphorylation autophosphorylation glycosylation crosstalk NSCLC
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2024.1436033/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
by: Lili Feng, et al.
Published: (2024-12-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases
by: Liqun Li, et al.
Published: (2024-12-01)

A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
by: Kai Sun, et al.
Published: (2024-12-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling
by: Jiahui Wu, et al.
Published: (2022-04-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling
by: Jiahui Wu, et al.
Published: (2024-12-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
by: Yao Li, et al.
Published: (2024-12-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
by: Mingfeng He, et al.
Published: (2025-01-01)

Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer
by: Zihua Zou, et al.
Published: (2025-01-01)

Implication of protein post translational modifications in gastric cancer
by: Houji Song, et al.
Published: (2025-02-01)

Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR
by: Duhita Mirikar, et al.
Published: (2025-01-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Research Note: Comprehensive proteomic, phosphoproteomic, and N-glycoproteomic analysis of chicken egg yolk plasma
by: Di Xiao, et al.
Published: (2024-12-01)

Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases
by: Vesna Ćeriman Krstić, et al.
Published: (2024-11-01)

Decoding post-translational modification for understanding stress tolerance in plant
by: Anuradha Pandey, et al.
Published: (2024-11-01)

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome
by: Mingyuan Du, et al.
Published: (2024-12-01)

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
by: Margaret Stalker, MD, et al.
Published: (2025-01-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC
by: Jiaxin Liu, et al.
Published: (2024-11-01)

Long-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT
by: Hirokazu Watari, et al.
Published: (2024-12-01)

Developing glycoproteomics reveals the role of posttranslational glycosylation in the physiological and pathological processes of male reproduction
by: Qingyuan Cheng, et al.
Published: (2024-09-01)

The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study
by: Asmaa A. Helal, et al.
Published: (2024-12-01)

Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
by: Shaoyi Cao, et al.
Published: (2024-12-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders
by: Zhong-hua Fu, et al.
Published: (2025-01-01)

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY
by: Jill Feldman, MA, et al.
Published: (2025-03-01)

Novel Cyclic Peptide–Drug Conjugate P6-SN38 Toward Targeted Treatment of EGFR Overexpressed Non-Small Cell Lung Cancer
by: Andrii Bazylevich, et al.
Published: (2024-12-01)

Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments
by: Yen‐Shou Kuo, et al.
Published: (2025-09-01)

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
by: Yi Dong, et al.
Published: (2024-12-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
by: Ji Eun Shin, et al.
Published: (2025-02-01)

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
by: Arianna Marinello, MD, et al.
Published: (2025-03-01)

DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
by: Ibrahim C. Haznedaroglu
Published: (2015-02-01)

Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review
by: Siyu Lei, et al.
Published: (2024-11-01)